MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells
出版年份 2019 全文链接
标题
MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells
作者
关键词
-
出版物
JOURNAL OF PATHOLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2019-04-12
DOI
10.1002/path.5280
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
- (2018) Chia-Wei Li et al. CANCER CELL
- Regulation and Function of the PD-L1 Checkpoint
- (2018) Chong Sun et al. IMMUNITY
- Progress in the Management of Advanced Thoracic Malignancies in 2017
- (2018) Roberto Ferrara et al. Journal of Thoracic Oncology
- Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma
- (2018) Michaël Cerezo et al. NATURE MEDICINE
- Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
- (2017) Matthew A. Coelho et al. IMMUNITY
- Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer
- (2017) Pasi A. Jänne et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Lung cancer: current therapies and new targeted treatments
- (2017) Fred R Hirsch et al. LANCET
- Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
- (2017) Riccardo Mezzadra et al. NATURE
- CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
- (2017) Marian L. Burr et al. NATURE
- S100A7 promotes lung adenocarcinoma to squamous carcinoma transdifferentiation, and its expression is differentially regulated by the Hippo-YAP pathway in lung cancer cells
- (2017) Rui Wang et al. Oncotarget
- Identifying Regulatory Posttranslational Modifications of PD-L1: A Focus on Monoubiquitinaton
- (2017) Henrick Horita et al. NEOPLASIA
- EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
- (2017) Zhong-Yi Dong et al. OncoImmunology
- The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
- (2017) Edmund Poon et al. Journal for ImmunoTherapy of Cancer
- PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis
- (2017) Minghui Zhang et al. Scientific Reports
- Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer
- (2016) C. A. Carter et al. ANNALS OF ONCOLOGY
- Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer
- (2016) Kurt A. Schalper et al. CLINICAL CANCER RESEARCH
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- (2016) Peter J.R. Ebert et al. IMMUNITY
- Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer
- (2016) Raffaele Califano et al. Current Oncology Reports
- Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
- (2016) Chia-Wei Li et al. Nature Communications
- Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
- (2016) E. J. Brea et al. Cancer Immunology Research
- Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer
- (2016) Angel Qin et al. Cancer Medicine
- Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer
- (2016) Adrian G. Sacher et al. JAMA Oncology
- Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer
- (2016) Jin S. Im et al. PLoS One
- RAS–Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers
- (2016) Hidetoshi Sumimoto et al. PLoS One
- Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN That Induce PD-L1 Expression in Head and Neck Cancer
- (2015) F. Concha-Benavente et al. CANCER RESEARCH
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer
- (2015) K. Ota et al. CLINICAL CANCER RESEARCH
- The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
- (2015) L. Liu et al. CLINICAL CANCER RESEARCH
- Novel Roles of c-Met in the Survival of Renal Cancer Cells through the Regulation of HO-1 and PD-L1 Expression
- (2015) Murugabaskar Balan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma
- (2015) Yuki Matsumura et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
- (2015) Nan Chen et al. Journal of Thoracic Oncology
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer
- (2014) Claudia Fumarola et al. BIOCHEMICAL PHARMACOLOGY
- Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-γ treatment
- (2014) Kousaku Mimura et al. CANCER SCIENCE
- Targeting the MET gene for the treatment of non-small-cell lung cancer
- (2013) F. Gelsomino et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells
- (2013) P. Leone et al. JNCI-Journal of the National Cancer Institute
- Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
- (2012) Marcin Imielinski et al. CELL
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors
- (2010) Andrey Loboda et al. BMC Medical Genomics
- Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
- (2010) J. R. Dry et al. CANCER RESEARCH
- Overexpression of Phospho-eIF4E Is Associated with Survival through AKT Pathway in Non-Small Cell Lung Cancer
- (2009) A. Yoshizawa et al. CLINICAL CANCER RESEARCH
- Molecular Mechanisms of IFN-γ to Up-Regulate MHC Class I Antigen Processing and Presentation
- (2009) Fang Zhou INTERNATIONAL REVIEWS OF IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now